• 약학회지
• /
• 제45권3호
• /
• pp.276-281
• /
• 2001

The present study was conducted to evaluate the effect of KST221085, a newly synthesized antidiabetic agent, on the hearts from streptozotocin (STZ)-induced diabetic rats. In isolated diabetic hearts, left ventricular developed pressure (LVDP), heart rate (HR) and coronary flow rate (CFR) were decreased compared to normal control, indicating cardiovascular dysfunction in diabetic heart. The treatment with 10 $\mu$M KST221085 remarkably improved the diabetes-induced contractile impairment, without any influence on HR. Reduced coronary flow in diabetic heart was also significantly increased by treatment with 10 $\mu$M KST221085. In isolated aorta from diabetic rat, treatment with 10 $\mu$M KST221085 increased endothelium-dependent relaxation, suggesting that KST221085 can improve the impaired endothelial function in diabetic aorta. Our results suggest that KST221085 treatment can improve the cardiovascular dysfunction in STZ-induced diabetic rats.

• 대한의용생체공학회:의공학회지
• /
• 제34권1호
• /
• pp.40-45
• /
• 2013

The conventional simulators used the expensive commercial artificial heart with a limited performance, and focused on replicating the heart function. The arterial pressure is the key factor of the cardiovascular disease. The purpose of this study is to develop a simulator focused on the pressure wave. The simulator is composed of a step motor, slider-crank mechanism, piston-cylinder, two check valves, a elastic tube, and two reservoirs. With the changes of design parameters, the functions of the simulator were evaluated. The simulator shows the good agreement of the characteristics of the cardiovascular system.

• Advances in biomechanics and applications
• /
• 제1권1호
• /
• pp.41-55
• /
• 2014

Acellular intra-myocardial biomaterial injections have been shown to be therapeutically beneficial in inhibiting ventricular remodelling of myocardial infarction (MI). Based on a biventricular canine cardiac geometry, various finite element models were developed that comprised an ischemic (II) or scarred infarct (SDI) in left ventricular (LV) antero-apical region, without and with intra-myocardial biomaterial injectate in layered (L) and bulk (B) distribution. Changes in myocardial properties and LV geometry were implemented corresponding to infarct stage (tissue softening vs. stiffening, infarct thinning, and cavity dilation) and injectate (infarct thickening). The layered and bulk injectate increased ejection fraction of the infarcted LV by 77% (II+L) and 25% (II+B) at the ischemic stage and by 61% (SDI+L) and 63% (SDI+B) at the remodelling stage. The injectates decreased the mean end-systolic myofibre stress in the infarct by 99% (II+L), 97% (II+B), 70% (SDI+L) and 36% (SDI+B). The bulk injectate was slightly more effective in improving LV function at the remodelling stage whereas the layered injectate was superior in functional improvement at ischemic stage and in reduction of wall stress at ischemic and remodelling stage. These findings may stimulate and guide further research towards tailoring acellular biomaterial injectate therapies for MI.

• Korean Circulation Journal
• /
• 제48권12호
• /
• pp.1148-1156
• /
• 2018

Background and Objectives: It is controversial that decreased left ventricular function could predict poststroke outcomes. The purpose of this study is to elucidate whether left ventricular ejection fraction (LVEF) can predict cardiovascular events and mortality in acute ischemic stroke (AIS) without atrial fibrillation (AF) and coronary heart disease (CHD). Methods: Transthoracic echocardiography was conducted consecutively in patients with AIS or transient ischemic attack at Soonchunhyang University Hospital between January 2008 and July 2016. The clinical data and echocardiographic LVEF of 1,465 patients were reviewed after excluding AF and CHD. Poststroke disability, major adverse cardiac events (MACE; nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death) and all-cause mortality during 1 year after index stroke were prospectively captured. Cox proportional hazards regressions analysis were applied adjusting traditional risk factors and potential determinants. Results: The mean follow-up time was $259.9{\pm}148.8days$ with a total of 29 non-fatal strokes, 3 myocardial infarctions, 33 cardiovascular deaths, and 53 all-cause mortality. The cumulative incidence of MACE and all-cause mortality were significantly higher in the lowest LVEF (<55) group compared with the others (p=0.022 and 0.009). In prediction models, LVEF (per 10%) had hazards ratios of 0.54 (95% confidence interval [CI], 0.36-0.80, p=0.002) for MACE and 0.61 (95% CI, 0.39-0.97, p=0.037) for all-cause mortality. Conclusions: LVEF could be an independent predictor of cardiovascular events and mortality after AIS in the absence of AF and CHD.

• Journal of Chest Surgery
• /
• 제42권3호
• /
• pp.401-403
• /
• 2009

63세 여자 환자의 악성 흉선종 절제수술 시에 횡격막 신경의 절제 및 복원술이 시행되었다. 수술 소견상 좌측 횡격막 신경이 2 cm정도의 길이로 종양에 완전히 둘러싸여 있어서 위아래로 5 mm 길이의 여유를 두고 3 cm정도의 횡격막 신경을 절제하였으며 직접 단단 문합 하였다. 수술 후 11개월에 시행한 투시진단에서 양측 횡격막은 적절하고 대칭적인 움직임을 보임으로서 신경기능의 회복을 시사했다. 수술 후 30개월에 시행한 폐 기능 검사 결과는 수술 전의 소견과 유사하였다. 환자는 재발 없이 현재 외래 추적 관찰 중이다.

• Journal of Chest Surgery
• /
• 제25권11호
• /
• pp.1318-1326
• /
• 1992

Backgroud. To determine the influence of age at operation upon surgical outcome in patients with isolated secundum atrial septal defect, retrospective clinical analysis was done. Material and method. From June, 1976 to December, 1991, 146 patients, 63 male and 83 female patients ranging in age from 13 months to 56 years, were operated on for isolated secundum atrial septal defect. The patients were divided into 3 groups according to their age at operation: Group I [<20 years old], 91 patients[62.3%]; Group II [21 to 40 years old], 44 patients[30.1%]; GroupIII[>41 years old], 11 patients[7.6%]. Significant differences in clinical features, hemodynamic function, early and late results between age groups were speculated. Results. One hundred thirty-one patients[89.6%] were symptomatic at the time of operation, the most common symptoms being dyspnea on exertion, recurrent respiratory infection, palpitation and chest pain. Patients in NYHA class III or IV were 3.3% in group I, 25% in groupIII, and 54.5% in group Ill. Hemodynamic data was available for 138 patients [94.5%]. Significant pulmonary hypertension [MPA systolic pressure $^3$ 40mmHg] was noted in 22 patients [15.9%]. Patients with pulmonary vascular disease [Rp/Rs>1.25] were 2% in group I, 7.3% in group Il, and 9.1% in groupIII. But there were no significant differences between the age groups in the size of the shunt or the ratio of pulmonary to systemic flow. Atrial septal defects were closed with direct suture in 144 patients and patch repair was performed in 2 patients with high defect. Atrial arrhythmia [8.2%] was the most common postoperative complication. The mean [LSD] duration of follow-up in all patients was 16$\pm$22 months [range, 1~96 months]. Functional result was excellent regardless of the age groups. During follow-up period, late cardiovascular events were arrhythmia [7 cases], reoperation for recurrent ASD [2 cases], and premature late death due to bacterial endocarditis [1 case]. Incidence of preoperative and late atrial fibrillation was significantly higher in older age group. Conclusion. Age at operation is one of the most important predictor of early and late surgical outcome with its impact on the following factors : 1] hemodynamic alterations and ventricular dysfunction due to longstanding volume and pressure overload, 2] pulmonary vascular disease, and 3] atrial arrhythmia including atrial fibrillation as a result of atrial dilatation. Therefore, among patients with surgically repaired atrial septal defects, those operated on over the age of 20 require careful supervision on the long-term basis.

• Journal of Chest Surgery
• /
• 제25권11호
• /
• pp.1218-1220
• /
• 1992

Pneumonectomy on a patient with documented poor pulmonary function indicating a contraindication to surgery can be associated with a high risk of serious postoperative morbidity or mortality. However the usual criterias, on the performance of a pneumonectomy on a high risk patient based on the preoperative assessment of the pulmonary function may not sometimes predict with accuracy the operative outcome in the postoperative period. We recently performed pneumonectomy with good results on a patient with poor pulmonary function that would otherwise have been an absolute contraindication to surgery by usual criteria.

• 한국콘텐츠학회논문지
• /
• 제9권7호
• /
• pp.225-232
• /
• 2009

연구는 심박수, 수축기 혈압, 이완기 혈압, 말초혈관 산소포화도 알아보고자 바닥과 스위스 볼상에서 요부안정화운동(LSE)에 따른 심혈관기능에 미치는 연구를 하였다. 대상자는 K 산업체 재활센타를 이용한 근골격계 근로자 중 선정기준에 적합한 남성 18명을 실험1군 바닥 적용군에 9명, 실험군 2군 스위스볼 적용군에 9명으로 분류하여 심박수, 수축기 혈압, 이완기 혈압, 말초혈관 산소포화도를 비교하였다. 심박수는 휴대용 심박 측정계(RS400sd, Finland)로, 혈압은 혈압계((FC-110, Japan)로, 말초혈관 산소포화도는 누리텍 체력 측정장치((TF-300-5, Korea)로 측정하고 분석하였다. 두군 모두 운동실시 후에 말초혈관 산소농도가 점차 통계학적으로 유의하게 증가하였으며, 수축기혈압이 통계학적으로 유의하게 감소하였다. 요부안정화운동에 따른 자세변동이 심혈관기능에 영향을 미치지만 지변의 상태에 따른 차이는 크게 영향을 받지 않는다는 결론을 얻었다.

• Journal of Chest Surgery
• /
• 제29권9호
• /
• pp.996-1002
• /
• 1996

전북대학교병원 흉부외과학 교실에서는 1979년 8월부터 1995년 8월까지 73례의 전폐절제술을 시행하였으며, 그 중 폐암이 53례, 폐결핵이 10례, 기관지 확장증이 4례, 기타가 6례 이었다. 73례에서 수술사 망율 및 합볏증을 조사하고 술후 6개월에 53명의 환자에서 폐기능 검사를 시행하여 이에 영향을미치는 인자(나이:성별, 병리소견(양성 또는 악성), 동반질환, 술전 폐기능 검사, 수술시간 등)를 통계학적으로 비교 분석하였다. 수술 사망율에 대해서는 술전 최대자발호기량(MW)의 예측치에 대한 백분율(P=0.013)과 수술시간 (P=0.009)이, 술후 합병증에 대해서는 염증성 질환(P=0.015)이, 그리고 술후 6개월후에 시행한 폐기능 검사치에 대해서는 술전 노력성 폐활량의 예측치에 대한 백분율(FVC(%. prod), p=0.0018),술전 1초간 강제 호기량의 예측치에 대한 백분율(FEVI 3%, prod), p=0.0024),술전 최대 자발성 호기량의 예측치에 대한 백분율(MW 3%. prod), p=0.0043) 등이 통계학적으로 의의 있게 나타났다. 결론적으로수술후의 사망율과 합병증을 줄이고 환자의 원활한 활동능력을 얻기 위해 술전의 환자의 전신상태,심혈관계 및 술전의 폐기능과술후의 保맨\ulcorner폐기능에 대한충분한 평가가 있어야 하며, 염증성 질환이 있는 환자는 염증및 분비물의 성상및 정도를 정확하게 평가하여야 할 것으로 사료된다.

• 생명과학회지
• /
• 제30권7호
• /
• pp.651-659
• /
• 2020

허혈성 심혈관질환은 전 세계적으로 치사율이 높은 질병 중 하나이다. 이를 치료하기 위해 수술적 방법이 시행되고 있으나, 손상된 심근조직 회복의 어려움과 수술 후 부작용의 한계가 남아있다. 이러한 한계점을 극복하기 위해, 최근 줄기세포를 기반으로 한 심혈관질환의 세포치료제가 각광받고 있는데 그 중에서도 특히 혈관내피전구세포(EPC)는 높은 증식능과 분화능을 기반으로 손상된 혈관을 재생하고, 주변 조직의 재생을 돕는다는 장점이 있다. 또, EPC는 임상적으로 안전하며, 환자의 심근 기능을 회복시켜주기에 잠재적인 심혈관질환 치료제로서의 가능성이 대두되었다. 하지만, 환자 유래 EPC를 이용한 치료법은, 고령, 흡연 여부, 기저질환 등의 이유로 환자의 EPC 기능이 저하되어 있어, 그 치료 효능을 기대하기 어렵다. 따라서, 최근에는 세포 프라이밍 기법, 오가노이드 배양법과 같이 EPC의 생리학적 활성도를 올리는 체외 배양법의 개발과 3D 바이오프린팅 기법을 이용한 EPC의 이식 효율을 높여 치료 효능을 개선시킬 수 있는 새로운 접근법이 연구되고 있다. 본 연구에서는 EPC의 특징과 세포치료제로서의 임상적용 가능성에 대해 살펴보고자 한다.